Previous 10 | Next 10 |
HAMPTON, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Cheryl L. Cohen and Dr. Garry Neil to the company’s Board of Directors. “We are thrilled to welcome Cheryl and Garry to our Board of Directors ...
HAMPTON, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference in New York City on Wednesday, June 8, 2022 at 8:30 a.m. ET. A webcas...
HAMPTON, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with antihistamine refractory chronic spontaneous urticaria (CSU), has been accepted as a late-brea...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today we’re looking at some micro-cap stocks to buy now and go long on hope. Apollo Medical ( AMEH ): Leadership has its privileges. Protagonist Therapeutics ( PTGX ): Behind solid execution comes lo...
Celldex press release (NASDAQ:CLDX): Q1 GAAP EPS of -$0.49 misses by $0.04. Revenue of $0.17M (-75.4% Y/Y) misses by $0.39M. Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at March 31, 2022 are sufficient to meet estimated working capital requir...
HAMPTON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “This quarter, we continued to focus on advancing our clinical programs and are ...
The following slide deck was published by Celldex Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Celldex Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
Celldex Therapeutics, Inc. (CLDX) Q4 2021 Earnings Conference Call February 28, 2022 04:30 PM ET Company Participants Sarah Cavanaugh - Senior Vice President, Corporate Affairs and Administration Anthony Marucci - Co-founder, President and Chief Executive Officer Tibor Keler - Co-Founder and ...
Celldex press release (NASDAQ:CLDX): Q4 GAAP EPS of -$0.43 misses by $0.02. Revenue of $0.33M (-91.3% Y/Y) misses by $0.84M. For further details see: Celldex GAAP EPS of -$0.43 misses by $0.02, revenue of $0.33M misses by $0.84M
CSU Phase 1b multi-dose data expected in July CDX-0159 subcutaneous formulation study results fully support transition to SubQ dosing; Phase 2 studies in CSU and CIndU to initiate Q2 2022 Expanded development of CDX-0159 into Eosinophilic Esophagitis (EoE) Well c...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...